$PDSB
PDS Biotechnology Corp

2019 Q2 Form 10-Q Financial Statement

#000114036119013922 Filed on August 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q4 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.720M $3.450M $3.340M
YoY Change -48.5% -34.78% -19.9%
% of Gross Profit
Research & Development $1.887M $490.0K $168.6K
YoY Change 1019.14% -95.48% -98.12%
% of Gross Profit
Depreciation & Amortization $40.00K $40.00K $40.00K
YoY Change 0.0% -20.0% -20.0%
% of Gross Profit
Operating Expenses $4.271M $3.930M $567.0K
YoY Change 653.21% -75.62% -95.69%
Operating Profit -$4.271M -$567.0K
YoY Change 653.21%
Interest Expense $0.00 $180.0K $804.00
YoY Change -100.0% -148.65% -100.22%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.890M -$5.870M -$12.68M
YoY Change -69.32% -64.4% -6.07%
Income Tax -$2.780M
% Of Pretax Income
Net Earnings -$3.886M -$3.090M -$567.8K
YoY Change 584.33% -77.77% -95.79%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$751.0K -$1.968M -$8.128M
COMMON SHARES
Basic Shares Outstanding 5.176M 3.338M
Diluted Shares Outstanding 5.176M 3.338M

Balance Sheet

Concept 2019 Q2 2018 Q4 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.70M $34.60M $46.00M
YoY Change -52.83% -60.73% -57.68%
Cash & Equivalents $21.73M $103.7K $405.2K
Short-Term Investments
Other Short-Term Assets $1.100M $1.000M $600.0K
YoY Change 83.33% 0.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.83M $122.1K $46.60M
YoY Change -51.0% -99.86% -57.4%
LONG-TERM ASSETS
Property, Plant & Equipment $369.0K $29.51K $500.0K
YoY Change -26.2% -99.13% -85.71%
Goodwill
YoY Change
Intangibles $1.223M $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $145.5K $12.80K $100.0K
YoY Change 45.47% -87.2% 0.0%
Total Long-Term Assets $2.971M $42.31K $600.0K
YoY Change 395.23% -98.79% -83.33%
TOTAL ASSETS
Total Short-Term Assets $22.83M $122.1K $46.60M
Total Long-Term Assets $2.971M $42.31K $600.0K
Total Assets $25.80M $164.4K $47.20M
YoY Change -45.33% -99.82% -58.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.853M $1.308M $1.700M
YoY Change 9.02% -70.28% -61.36%
Accrued Expenses $638.2K $601.9K $6.000M
YoY Change -89.36% -88.85% 46.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.267M $1.909M $13.90M
YoY Change -69.3% -85.2% 19.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $800.0K
YoY Change
Total Long-Term Liabilities $800.0K $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.267M $1.909M $13.90M
Total Long-Term Liabilities $800.0K $0.00 $0.00
Total Liabilities $5.200M $2.231M $13.90M
YoY Change -62.59% -92.61% -51.57%
SHAREHOLDERS EQUITY
Retained Earnings -$18.08M -$21.94M
YoY Change
Common Stock $1.709K $19.87M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.61M -$2.066M -$807.6K
YoY Change
Total Liabilities & Shareholders Equity $25.80M $164.4K $47.20M
YoY Change -45.33% -99.82% -58.23%

Cashflow Statement

Concept 2019 Q2 2018 Q4 2018 Q2
OPERATING ACTIVITIES
Net Income -$3.886M -$3.090M -$567.8K
YoY Change 584.33% -77.77% -95.79%
Depreciation, Depletion And Amortization $40.00K $40.00K $40.00K
YoY Change 0.0% -20.0% -20.0%
Cash From Operating Activities -$4.860M -$2.170M -$8.120M
YoY Change -40.15% -76.52% -12.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -20.90M
YoY Change -100.0% -100.0% -193.18%
NET CHANGE
Cash From Operating Activities -4.860M -2.170M -8.120M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 0.000 -20.90M
Net Change In Cash -4.860M -2.170M -29.02M
YoY Change -83.25% -76.54% -321.19%
FREE CASH FLOW
Cash From Operating Activities -$4.860M -$2.170M -$8.120M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.170M -$8.120M
YoY Change -76.44% -12.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
PDS Biotechnology Corp
dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5177487
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1412951
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1853306
CY2019Q2 us-gaap Accrued Rent Current
AccruedRentCurrent
0
CY2018Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
8000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
638186
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
601889
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421617
CY2019Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
242732
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19311529
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
38686233
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
44000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
342105
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7645
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
630
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2773451
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18580
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2773451
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51642
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44627
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18580
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1681059
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
638610
CY2019Q2 us-gaap Assets
Assets
25804346
CY2018Q4 us-gaap Assets
Assets
344323
CY2019Q2 us-gaap Assets Current
AssetsCurrent
22832995
CY2018Q4 us-gaap Assets Current
AssetsCurrent
260323
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-7.37
CY2018Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-2.70
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-4.44
CY2019Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-2.84
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-19809603
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-34823458
CY2018Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-13245463
CY2019Q2 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-14686971
CY2018Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-2.70
CY2019Q2 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-2.84
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-4.44
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-7.37
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
11939331
CY2018Q2 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0
CY2019Q2 us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
209449
CY2019Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21734152
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
103695
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
21630457
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
229277
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175884
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103695
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21734152
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
405161
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
29106512
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103695
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21734152
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.87
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00033
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3417187
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5177487
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3417187
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5177487
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1128
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1709
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3885852
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-567831
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1305723
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2930847
CY2019Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3573760
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
30000
CY2019Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
32953
CY2019Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
157000
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
25244
us-gaap Depreciation
Depreciation
14297
us-gaap Depreciation
Depreciation
62706
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1937920
CY2018Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-157273
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-20210
CY2019Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1223000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
41692
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
934226
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2383972
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
398425
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6289848
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.17
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.41
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.66
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.75
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.41
CY2019Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.75
CY2018Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.17
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.52
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
0
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-786396
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
171960
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1157171
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
227911
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-292678
us-gaap Interest Expense
InterestExpense
606
CY2019Q2 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
1763
CY2018Q2 us-gaap Interest Expense
InterestExpense
804
us-gaap Interest Paid Net
InterestPaidNet
606
us-gaap Interest Paid Net
InterestPaidNet
1753
us-gaap Investment Income Interest
InvestmentIncomeInterest
10
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4
us-gaap Investment Income Interest
InvestmentIncomeInterest
198907
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
175605
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1430978
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
297221
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
164614
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
530386
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
603371
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
11400
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
20300
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
15644
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
31287
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344323
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25804346
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2014840
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4267453
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4270906
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-567031
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="text-align: left; font-weight: bold;">Note 1 <font style="font-size: 11pt;">&#8211;</font> Nature of Operations</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">PDS Biotechnology Corporation, a Delaware corporation (the &#8220;Company,&#8221; &#8220;PDS&#8221; or the &#8220;combined company&#8221;), is a clinical stage immuno-oncology company with a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers.&#160; All of PDS&#8217;s products are based on the proprietary Versamune<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">On March 15, 2019, the Company, then operating as Edge Therapeutics, Inc. (&#8220;Edge&#8221;), completed its reverse merger with privately held PDS Biotechnology Corporation (&#8220;Private PDS&#8221;), pursuant to and in accordance with the terms of the Agreement and Plan of Merger, dated as of November 23, 2018, as amended on January 24, 2019, by and among the Company, Echos Merger Sub, a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), and Private PDS, whereby Private PDS merged with and into Merger Sub, with Private PDS surviving as the Company&#8217;s wholly-owned subsidiary (the &#8220;Merger&#8221;).<font style="font-style: italic;">&#160;</font>In connection with and immediately following completion of the Merger, the Company effected a 1-for-20 reverse stock split (the &#8220;Reverse Stock Split&#8221;) and changed its corporate name from Edge Therapeutics, Inc. to PDS Biotechnology Corporation, and Private PDS changed its name to PDS Operating Corporation.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">For accounting purposes, the Merger is treated as a &#8220;reverse acquisition&#8221; under generally accepted accounting principles in the United States (&#8220;U.S. GAAP&#8221;) and Private PDS is considered the accounting acquirer. Accordingly, upon consummation of the Merger, the historical financial statements of Private PDS became the Company&#8217;s historical financial statements, and the historical financial statements of Private PDS are included in the comparative prior periods. See &#8220;Note 3 &#8211; Reverse Merger&#8221; for more information on the Merger. As part of the Merger, the Company acquired all of Edge&#8217;s assets relating to current and future research and development.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;">From the Company&#8217;s inception, it has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, acquiring operating assets, planning and executing clinical trials and raising capital.</div></div>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-819703
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8226055
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
29106512
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1048980
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
750000
us-gaap Net Income Loss
NetIncomeLoss
-1305723
us-gaap Net Income Loss
NetIncomeLoss
2930847
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-567831
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3885852
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
0
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
15793638
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1233894
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
172635
CY2019Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
147973
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
4270906
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
567031
us-gaap Operating Expenses
OperatingExpenses
9206785
us-gaap Operating Expenses
OperatingExpenses
1303970
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1015
us-gaap Operating Income Loss
OperatingIncomeLoss
-1303970
us-gaap Operating Income Loss
OperatingIncomeLoss
-9206785
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
48930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8887
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
750000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
492086
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
774278
us-gaap Operating Lease Payments
OperatingLeasePayments
172635
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1266364
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12800
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
145470
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46674
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
786396
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1098843
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
156628
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1056002
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
750000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
750000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368987
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29508
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1384810
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
7022
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2916937
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
369744
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1886934
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
168606
CY2019Q2 us-gaap Restructuring Reserve
RestructuringReserve
1283875
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2018Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
CY2019Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1283875
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21013174
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-18082327
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9443
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.31
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0234
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0219
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
32953
CY2019Q1 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
1599178
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
25243
CY2019Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
25244
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
15793638
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
801894
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M1D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y0M29D
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
us-gaap Share Based Compensation
ShareBasedCompensation
2773451
us-gaap Share Based Compensation
ShareBasedCompensation
51642
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.0000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
20605615
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1700517
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
24447643
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-284406
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-609528
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-807607
CY2019Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2019Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"><tr><td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">(B)</td><td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-weight: bold;">Use of estimates:</div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div>
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1211335
CY2019Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2018Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3170804
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5175837
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3338214
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4466025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3170804
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5677360
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3338214
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5175837
CY2019Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
304225
CY2018Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
54269
CY2019Q1 pdsb Class Of Warrant Or Right Number Of Warrants Issued
ClassOfWarrantOrRightNumberOfWarrantsIssued
34192
CY2018Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
71329
CY2019Q2 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
91229
pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
0
CY2019Q2 pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
0
pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
299000
CY2018Q2 pdsb Consultant Agreements Expenses
ConsultantAgreementsExpenses
181500
CY2019Q1 pdsb Number Of Putative Class Action Lawsuits
NumberOfPutativeClassActionLawsuits
2
CY2019Q1 pdsb Number Of Individual Lawsuits
NumberOfIndividualLawsuits
2
CY2018Q2 pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
13072199
CY2019Q2 pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
14388478
pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
33905229
pdsb Business Acquisition Pro Forma Operating Expenses
BusinessAcquisitionProFormaOperatingExpenses
19324357
CY2018Q4 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2019Q1 pdsb In The Money Shares Paid Out In Cash
InTheMoneySharesPaidOutInCash
753
CY2019Q1 pdsb Fractional Shares Paid Out In Cash
FractionalSharesPaidOutInCash
235
pdsb Stock Issued During Period Value Antidilution Protection
StockIssuedDuringPeriodValueAntidilutionProtection
0
CY2019Q2 pdsb Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
5
CY2019Q1 pdsb Conversion Of Stock Shares Converted
ConversionOfStockSharesConverted
0.3262

Files In Submission

Name View Source Status
0001140361-19-013922-index-headers.html Edgar Link pending
0001140361-19-013922-index.html Edgar Link pending
0001140361-19-013922.txt Edgar Link pending
0001140361-19-013922-xbrl.zip Edgar Link pending
ex10_12.htm Edgar Link pending
ex10_13.htm Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10q.htm Edgar Link pending
image0.jpg Edgar Link pending
image00001.jpg Edgar Link pending
pdsb-20190630.xml Edgar Link completed
pdsb-20190630.xsd Edgar Link pending
pdsb-20190630_cal.xml Edgar Link unprocessable
pdsb-20190630_def.xml Edgar Link unprocessable
pdsb-20190630_lab.xml Edgar Link unprocessable
pdsb-20190630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending